Most recent by Paul Forfia, MD
Winrevair PAH trial stopped due to earlier ‘robust evidence’
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous trials, according to a press release.
Speaker Two Article Four: Nullam euismod, quam ut viverra auctor
Cras feugiat lectus orci, ut sagittis ligula pulvinar luctus. Mauris non enim et lorem molestie commodo in sit amet velit. Curabitur consectetur dictum sem.
Speaker Two Article Six: Nullam euismod
Cras feugiat lectus orci, ut sagittis ligula pulvinar luctus. Mauris non enim et lorem molestie commodo in sit amet velit. Curabitur consectetur dictum sem.
Speaker Two Article Three: Nullam euismod, quam ut viverra auctor
Cras feugiat lectus orci, ut sagittis ligula pulvinar luctus. Mauris non enim et lorem molestie commodo in sit amet velit. Curabitur consectetur dictum sem.
Speaker Two Article Two: Nullam euismod, quam ut viverra auctor
Cras feugiat lectus orci, ut sagittis ligula pulvinar luctus. Mauris non enim et lorem molestie commodo in sit amet velit. Curabitur consectetur dictum sem.
Speaker Two Article Five: Nullam euismod, quam ut viverra auctor
Cras feugiat lectus orci, ut sagittis ligula pulvinar luctus. Mauris non enim et lorem molestie commodo in sit amet velit. Curabitur consectetur dictum sem.
Speaker Two Article One: Nullam euismod, quam ut viverra auctor
Cras feugiat lectus orci, ut sagittis ligula pulvinar luctus. Mauris non enim et lorem molestie commodo in sit amet velit. Curabitur consectetur dictum sem.
Pregnancy should not be ruled out for all women with pulmonary hypertension
A patient in her early 30s with a history of severe pulmonary hypertension came into my office and expressed that she would like to start a family.